Zhitong Finance App News, ST Renfu (600079.SH) issued an announcement. The company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) recently publicized the registration information for phase II clinical trials of RFUS-188 injection on the drug clinical trial registration and information disclosure platform of the State Drug Administration.

Test name: To evaluate the efficacy and safety of RFUS-188 injection for analgesia after abdominal surgery, a multicenter, randomized, double-blind, parallel, placebo/positive control, two-stage design. The purpose of the clinical trial is: (1) to explore the effective dosage (PartA) of RFUS-188 injection for postoperative analgesia; (2) to evaluate the efficacy and safety of RFUS-188 injection for postoperative analgesia (Part B). Secondary objective: To explore the PK/PD characteristics of repeated administration of RFUS-188 injection for postoperative analgesia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.